Marker Therapeutics Inc —— 财务报表 (NASDAQ:MRKR) | MetaTrader

展开完整图表

新闻

MARKER THERAPEUTICS, INC. (MRKR) Reports Q4 Loss, Tops Revenue Estimates

Profound Medical (PROF) Reports Q4 Loss, Misses Revenue Estimates

Marker Therapeutics确定2026年股东大会日期和提案截止期限

Marker Therapeutics sets date for 2026 annual shareholder meeting and proposal deadline

MRKR Stock Up Nearly 114% in 3 Months: Here's What You Need to Know

Zacks Industry Outlook Highlights Soleno Therapeutics, Nektar Therapeutics, Rigel Pharmaceuticals, Ironwood Pharmaceuticals and Marker Therapeutics

MARKER THERAPEUTICS, INC. (MRKR) Now Trades Above Golden Cross: Time to Buy?

5 Small Drug Stocks to Buy as Industry Recovery Picks Up

H.C. Wainwright维持Marker Therapeutics股票买入评级

Marker Therapeutics stock maintains Buy rating at H.C. Wainwright

Brookline Capital将Marker Therapeutics股票目标价上调至5.60美元

Brookline Capital raises Marker Therapeutics stock price target to $5.60